Frontage Appoints Hugh Davis as Chief Business Officer
Frontage Laboratories, Inc., is pleased to announce the appointment of Dr. Hugh Davis as Chief Business Officer (CBO), in charge of Business Development, Sales, Marketing and Strategic Partnerships.
Hugh has over 30 years of experience in the pharmaceutical industry. His most recent position was with Johnson & Johnson where he has served as Vice President and Head of Biologics Development Sciences in the Janssen BioTherapeutics (JBIO) division of Janssen R&D, LLC since 2001. JBIO is responsible for creating and characterizing all biologic assets for J&J, across all therapeutic areas. In this role, Hugh participated in the development and approval of many biologic therapies including Remicade®, Stelara®, Simponi®, Sylvant®, Darzalex® and Tremfya®. Prior to J&J, Hugh led the Pharmacodynamics & Exploratory Research Laboratory in the Clinical Pharmacology Unit at Glaxo SmithKline from 1996 to 2001.
Hugh has published over 75 manuscripts in refereed journals, book chapters and invited review articles in areas of therapeutic drug discovery, clinical pharmacology and development in immunology, oncology, metabolic disease, bone metabolism and cardiovascular medicine.
Following receipt of his Bachelor’s degree in Chemistry from Gannon University in 1980 and Master’s and Doctorate degrees in Biochemistry from Villanova University in 1983 and 1985, Hugh completed a Post-Doctoral Fellowship at Centocor, Inc. where he patented the characterization of the CA 125 cancer antigen, a marker used in the diagnosis of ovarian cancer. Hugh has taught Chemistry, Biochemistry and Physics at Delaware County Community College, Immaculata University, Thomas Jefferson University and for 30 years at Villanova University, primarily teaching Allied Health majors in General, Biochemistry and Organic Chemistry. Hugh is a member of the Villanova University College of Liberal Arts and Sciences Dean’s Advisory Council.